Hyperuricemia Clinical Trial Pipeline Analysis: 15+ Key Companies Shaping the Future of Hyperuricemia Therapeutics | DelveInsight

DelveInsight's Hyperuricemia Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Hyperuricemia therapies in various stages of clinical development. The report provides insights into 15+ companies and 20+ pipeline drugs, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Hyperuricemia Clinical Trial Landscape Report

• DelveInsight's Hyperuricemia pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hyperuricemia treatment.
• Key Hyperuricemia companies such as Sobi, InventisBio Co., Ltd, Protalix Biotherapeutics, Jiangsu HengRui Medicine Co., Ltd., Intelligem Therapeutics Australia Pty Ltd., Atom Therapeutics, Shanton Pharma Holdings Limited, Novo Nordisk A/S, BioRay Pharmaceutical Co., Ltd., 3SBio Inc., and others.
• Promising Hyperuricemia pipeline therapies in various stages of development include AR882, D-0120, PRX-115, HR091506, IG3018, ABP-671, SAP-001, NNC4004-0002, BR2251, SSS11, and others.

Request a sample and discover the recent advances in Hyperuricemia treatment drugs https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Hyperuricemia?

Hyperuricemia is defined as an elevated serum uric acid level, usually greater than 6 mg/dL in women and 7 mg/dL in men. It occurs when the body produces too much uric acid, does not excrete enough, or both. Elevated uric acid can form sharp crystals that settle in the joints and cause gout, while accumulation in the kidneys can contribute to kidney stone formation.
Hyperuricemia often causes no symptoms until complications such as gout or kidney stones develop. When symptoms occur, they may include intense and sudden joint pain, particularly in the big toe, swelling, redness, joint stiffness, and kidney-related symptoms.

Emerging Hyperuricemia Drug Profiles

AR882: Sobi
AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which is responsible for a majority of reabsorption of filtered uric acid from the renal tubular lumen. By inhibiting URAT1, AR882 increases uric acid urinary excretion and thereby lowers serum uric acid (sUA). Currently, the drug is being evaluated in the Phase III stage of development for the treatment of Hyperuricemia.

D-0120: InventisBio Co., Ltd
D-0120 is a novel oral selective uric acid transporter (URAT1) inhibitor being developed for the treatment of Hyperuricemia and gout. It works by blocking the reabsorption of uric acid within the renal proximal tubule, thereby reducing serum uric acid concentrations. Currently, the drug is being evaluated in the Phase II stage of development for the treatment of Hyperuricemia.

PRX-115: Protalix Biotherapeutics
PRX-115 is a recombinant PEGylated uricase enzyme and chemically modified enzyme in development for the potential treatment of uncontrolled gout. The uricase enzyme converts uric acid to allantoin, which is easily eliminated through urine. Currently, PRX-115 is being evaluated in the Phase II stage of development for the treatment of Hyperuricemia.

Learn more about the novel and emerging Hyperuricemia pipeline therapies https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Hyperuricemia Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Hyperuricemia Companies: Sobi, InventisBio Co., Ltd, Protalix Biotherapeutics, Jiangsu HengRui Medicine Co., Ltd., Intelligem Therapeutics Australia Pty Ltd., Atom Therapeutics, Shanton Pharma Holdings Limited, Novo Nordisk A/S, BioRay Pharmaceutical Co., Ltd., 3SBio Inc.
• Key Hyperuricemia Pipeline Therapies: AR882, D-0120, PRX-115, HR091506, IG3018, ABP-671, SAP-001, NNC4004-0002, BR2251, SSS11

Dive deep into rich insights for new drugs for Hyperuricemia treatment, visit https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Hyperuricemia Pipeline Report Introduction
2. Hyperuricemia Pipeline Report Executive Summary
3. Hyperuricemia: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hyperuricemia Pipeline Therapeutics
6. Hyperuricemia Pipeline: Late Stage Products (Phase III)
7. Hyperuricemia Pipeline: Mid Stage Products (Phase II)
8. Hyperuricemia Pipeline: Early Stage Products (Phase I)
9. Hyperuricemia Pipeline: Preclinical and Discovery Stage Products
10. Hyperuricemia Pipeline Therapeutics Assessment
11. Inactive Products in the Hyperuricemia Pipeline
12. Key Companies
13. Key Products in the Hyperuricemia Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Hyperuricemia pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.